Last Updated | 31 March 2026

LOXO-RET-18036

A Phase I/II Study of the Oral RET inhibitor LOXO 292 in Paediatric patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumours
External Registry
Site Status Sydney Children's Hospital Royal Children's Hospital
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Recurrent/refractory
National Sponsor Loxo Oncology, Inc.
Open Date 01/07/2019
Conditions Medullary Thyroid Cancer
Infantile Myofibromatosis
Infantile Fibrosarcoma
Papillary Thyroid Cancer
Soft Tissue Sarcoma
Patient Range 6 months21 years
Disease Type Brain and Spinal (Central Nervous System) Tumours, Endocrine Tumours, Soft Tissue and Bone Tumours (Sarcoma)
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.